First name: France
  Last name: Mentré
  Function: IAME Vice Director, BiPID Director
  Position: Professor of Biostatistics
  Email: france.mentre

Research interest

My research is focused on development and application of methods for nonlinear mixed-effects models in pharmacokinetics and pharmacodynamics for more than 30 years. I am leading the development of the software PFIM for optimal design in pharmacometrics. I wish to extend the application of mixed-effects models for the systematic analysis of longitudinal data in clinical trials and cohorts. I focus more specifically in the treatment of infectious diseases, where pharmacometrics provides better insight on the variability of response to drugs and the acquisition of resistance.



1993 Habilitation à Diriger des Recherches, University Paris 6
1992 Medical Dissertation, University Paris 6
1984 PHD in Biomathematics, University Paris 7
1980-1984 Student of the Ecole Normale Supérieure in Mathematics

Academic positions

Since 2000 Professor of Biostatistics, School of Medicine, Université Paris Cité
1995-2000 Research Director at INSERM
1985-1995 Researcher at INSERM

Research training (post doctoral)

Since 2014 Vice Director of research unit UMR 1137 INSERM– University Paris 7:
“Infection . Antimicrobials. Modelling . Evolution”
Co leader of team “Biostatistical Modelling, Clinical Investigation and Pharmacometrics in Infection Diseases”
2003 –2013 Director of research unit UMR 738 INSERM– University Paris 7: “Models and Methods for the therapeutic assessment of chronic diseases”
Head of team “Biostatistical Modelling and Pharmacometrics”
1995-2000 Head of team: “Modelling of pharmacological processes; application to the analysis of clinical trial and to therapeutic drug monitoring” in INSERM UMR U436 INSERM – University Paris 6 : “Mathematical and Statistical Modelling in Biology and Medicine” (director Pr A Mallet)

Exhaustive list of publications


de Lamballerie X, Martin-Blondel G, Dupont A, Izopet J, Mentré F, Kamar N, Autran B, Paintaud G, Caillard S, le Bourgeois A, Richez C, Couzi L, Xhaard A, Marjanovic Z, Avouac J, Jacquet C, Anglicheau D, Cheminant M, Yazdanpanah Y, Guyen SN, Terrier B, Gottenberg JE, Besson C, Letrou S, Kali S, Angoulvant D, Sanchez VP, Tardivon C, Blancho G, Lévy V
Low serum neutralization of Omicron variants a month after AZD7442 prophylaxis initiation.
The Journal of Infection 2023, 86, 66-117.

Terzić V, Levoyer L, Figarella M, Bigagli E, Mercier N, De Gastines L, Gibowski S, Trøseid M, Demotes J, Olsen IC, Hites M, Ader F, Arribas Lopez JR, Mentré F, Espérou H, Costagliola D, Røttingen JA, Poissy J, Rozé JC, Warris A, O'Leary J, Fernandes RM, Assoumou L, Hankard R, Turner MA, Yazdanpanah Y, Diallo A, ERsg, csg
Implementation of a Centralised Pharmacovigilance System in Academic Pan-European Clinical Trials: Experience from EU-Response and Conect4Children Consortia.
British Journal of Clinical Pharmacology 2023


Guk J, Bridier-Nahmias A, Magnan M, Grall N, Duval X, Clermont O, Ruppé E, d'Humières C, Tenaillon O, Denamur E, Mentré F, Guedj J, Burdet C, Csg
Modeling the bacterial dynamics in the gut microbiota following an antibiotic-induced perturbation.
CPT: pharmacometrics & systems pharmacology 2022, 11, 906-918.

Lavalley-Morelle A, Timsit JF, Mentré F, Mullaert J, On
Joint modeling under competing risks: Application to survival prediction in patients admitted in Intensive Care Unit for sepsis with daily Sequential Organ Failure Assessment score assessments.
CPT: pharmacometrics & systems pharmacology 2022, 11, 1472-1484.

Guhl M, Mercier F, Hofmann C, Sharan S, Donnelly M, Feng K, Sun W, Sun G, Grosser S, Zhao L, Fang L, Mentré F, Comets E, Bertrand J
Impact of model misspecification on model-based tests in PK studies with parallel design: real case and simulation studies.
Journal of Pharmacokinetics and Pharmacodynamics 2022, 49, 557-577.

ERig, Diallo A, Trøseid M, Simensen VC, Boston A, Demotes J, Olsen IC, Chung F, Paiva JA, Hites M, Ader F, Arribas JR, Baratt-Due A, Melien Ø, Tacconelli E, Staub T, Greil R, Tsiodras S, Briel M, Esperou H, Mentré F, Eustace J, Saillard J, Delmas C, LeMestre S, Dumousseaux M, Costagliola D, Røttingen JA, Yazdanpanah Y
Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2022, 28, 1-5.

Eloy P, Laouénan C, Beavogui AH, Keita S, Manchon P, Etard JF, Sissoko D, Mentré F, Malvy D
High doses of favipiravir in two men survivors of Ebola virus disease carrying Ebola virus in semen in Guinea.
IDCases 2022, 27, e01412.

Lafaurie M, Burdet C, Hammas K, Goldwirt L, Berçot B, Sauvageon H, Houze P, Fourmont M, Mentré F, Molina JM
Population pharmacokinetics and pharmacodynamics of imipenem in neutropenic adult patients.
Infectious Diseases Now 2022, S2666-9919(22)00212-3.

Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Poissy J, Belhadi D, Diallo A, Lê MP, Peytavin G, Staub T, Greil R, Guedj J, Paiva JA, Costagliola D, Yazdanpanah Y, Burdet C, Mentré F, DSG
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.
The Lancet. Infectious Diseases 2022, 22, 209-221.

Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Mentré F, Burdet C, DSG
Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19.
The Lancet. Infectious Diseases 2022, 22, 764-765.

Möllenhoff K, Loingeville F, Bertrand J, Nguyen TT, Sharan S, Zhao L, Fang L, Sun G, Grosser S, Mentré F, Dette H
Efficient model-based bioequivalence testing.
Biostatistics (Oxford, England) 2022, 23, 314-327.

Vehreschild MJGT, Ducher A, Louie T, Cornely OA, Feger C, Dane A, Varastet M, Vitry F, de Gunzburg J, Andremont A, Mentré F, Wilcox MH
An open randomized multicentre Phase 2 trial to assess the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized patients treated with fluoroquinolones.
The Journal of Antimicrobial Chemotherapy 2022, 77, 1155-1165.

Lingas G, Néant N, Gaymard A, Belhadi D, Peytavin G, Hites M, Staub T, Greil R, Paiva JA, Poissy J, Peiffer-Smadja N, Costagliola D, Yazdanpanah Y, Wallet F, Gagneux-Brunon A, Mentré F, Ader F, Burdet C, Guedj J, Bouscambert-Duchamp M
Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial.
The Journal of Antimicrobial Chemotherapy 2022, 77, 1404-1412.

Delavy M, Burdet C, Sertour N, Devente S, Docquier JD, Grall N, Volant S, Ghozlane A, Duval X, Mentré F, d'Enfert C, Bougnoux ME, PSG
A Clinical Study Provides the First Direct Evidence That Interindividual Variations in Fecal β-Lactamase Activity Affect the Gut Mycobiota Dynamics in Response to β-Lactam Antibiotics.
mBio 2022, 13, e0288022.

Bouzid D, Mullaert J, Ghazali A, Ferré VM, Mentré F, Lemogne C, Ruszniewski P, Faye A, Dinh AT, Mirault T, UPCOsg
eOSCE stations live versus remote evaluation and scores variability.
BMC medical education 2022, 22, 861.

Belhadi D, El Baied M, Mulier G, Malvy D, Mentré F, Laouénan C
The number of cases, mortality and treatments of viral hemorrhagic fevers: A systematic review.
PLoS neglected tropical diseases 2022, 16, e0010889.


Pinquier JL, Varastet M, Meyers D, Sayah-Jeanne S, Féger C, Gaumétou O, Corbel T, de Gunzburg J, Mentré F, Ducher A
A Colon-Targeted Adsorbent (DAV132) Does Not Affect the Pharmacokinetics of Warfarin or Clonazepam in Healthy Subjects.
Clinical Pharmacology in Drug Development 2021, 10, 908-917.

Guk J, Guedj J, Burdet C, Andremont A, de Gunzburg J, Ducher A, Mentré F
Modeling the Effect of DAV132, a Novel Colon-Targeted Adsorbent, on Fecal Concentrations of Moxifloxacin and Gut Microbiota Diversity in Healthy Volunteers.
Clinical Pharmacology and Therapeutics 2021, 109, 1045-1054.

Couffignal C, Mentré F, Bertrand J
Impact of study design and statistical model in pharmacogenetic studies with gene-treatment interaction.
CPT: pharmacometrics & systems pharmacology 2021, 10, 340-349.

French J, Mentré F
Welcome to the statistics and pharmacometrics themed issue.
CPT: pharmacometrics & systems pharmacology 2021, 10, 273-274.

Rowland Yeo K, Hennig S, Krishnaswami S, Strydom N, Ayyar VS, French J, Sinha V, Sobie E, Zhao P, Friberg LE, Mentré F
CPT: Pharmacometrics & Systems Pharmacology - Inception, Maturation, and Future Vision.
CPT: pharmacometrics & systems pharmacology 2021, 10, 649-657.

Bauer RJ, Hooker AC, Mentre F
Tutorial for $DESIGN in NONMEM: Clinical Trial Evaluation and Optimization.
CPT: pharmacometrics & systems pharmacology 2021

Buatois S, Ueckert S, Frey N, Retout S, Mentré F
cLRT-Mod: An efficient methodology for pharmacometric model-based analysis of longitudinal phase II dose finding studies under model uncertainty.
Statistics in Medicine 2021, 40, 2435-2451.

Ghosn J, Piroth L, Epaulard O, Le Turnier P, Mentré F, Bachelet D, Laouénan C, FCcsaig
Persistent COVID-19 symptoms are highly prevalent 6 months after hospitalization: results from a large prospective cohort.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2021, 27, 1041.e1-1041.e4.

Ader F, Peiffer-Smadja N, Poissy J, Bouscambert-Duchamp M, Belhadi D, Diallo A, Delmas C, Saillard J, Dechanet A, Mercier N, Dupont A, Alfaiate T, Lescure FX, Raffi F, Goehringer F, Kimmoun A, Jaureguiberry S, Reignier J, Nseir S, Danion F, Clere-Jehl R, Bouiller K, Navellou JC, Tolsma V, Cabié A, Dubost C, Courjon J, Leroy S, Mootien J, Gaci R, Mourvillier B, Faure E, Pourcher V, Gallien S, Launay O, Lacombe K, Lanoix JP, Makinson A, Martin-Blondel G, Bouadma L, Botelho-Nevers E, Gagneux-Brunon A, Epaulard O, Piroth L, Wallet F, Richard JC, Reuter J, Staub T, Lina B, Noret M, Andrejak C, Lê MP, Peytavin G, Hites M, Costagliola D, Yazdanpanah Y, Burdet C, Mentré F, Dsg
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2021, 27, 1826-1837.

Seurat J, Tang Y, Mentré F, Nguyen TT
Finding optimal design in nonlinear mixed effect models using multiplicative algorithms.
Computer Methods and Programs in Biomedicine 2021, 207, 106126.

van Werkhoven CH, Ducher A, Berkell M, Mysara M, Lammens C, Torre-Cisneros J, Rodríguez-Baño J, Herghea D, Cornely OA, Biehl LM, Bernard L, Dominguez-Luzon MA, Maraki S, Barraud O, Nica M, Jazmati N, Sablier-Gallis F, de Gunzburg J, Mentré F, Malhotra-Kumar S, Bonten MJM, Vehreschild MJGT, ASG
Incidence and predictive biomarkers of Clostridioides difficile infection in hospitalized patients receiving broad-spectrum antibiotics.
Nature Communications 2021, 12, 2240.

Néant N, Lingas G, Le Hingrat Q, Ghosn J, Engelmann I, Lepiller Q, Gaymard A, Ferré V, Hartard C, Plantier JC, Thibault V, Marlet J, Montes B, Bouiller K, Lescure FX, Timsit JF, Faure E, Poissy J, Chidiac C, Raffi F, Kimmoun A, Etienne M, Richard JC, Tattevin P, Garot D, Le Moing V, Bachelet D, Tardivon C, Duval X, Yazdanpanah Y, Mentré F, Laouénan C, Visseaux B, Guedj J, FCCIaFCSg
Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort.
Proceedings of the National Academy of Sciences of the United States of America 2021, 118,

Lê MP, Peiffer-Smadja N, Guedj J, Neant N, Mentré F, Ader F, Yazdanpanah Y, Peytavin G, C21DFSC
Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial-authors' response.
The Journal of Antimicrobial Chemotherapy 2021, 76, 277-279.

Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, Manry J, Michailidis E, Hoffmann HH, Eto S, Garcia-Prat M, Bizien L, Parra-Martínez A, Yang R, Haljasmägi L, Migaud M, Särekannu K, Maslovskaja J, de Prost N, Tandjaoui-Lambiotte Y, Luyt CE, Amador-Borrero B, Gaudet A, Poissy J, Morel P, Richard P, Cognasse F, Troya J, Trouillet-Assant S, Belot A, Saker K, Garçon P, Rivière JG, Lagier JC, Gentile S, Rosen LB, Shaw E, Morio T, Tanaka J, Dalmau D, Tharaux PL, Sene D, Stepanian A, Megarbane B, Triantafyllia V, Fekkar A, Heath JR, Franco JL, Anaya JM, Solé-Violán J, Imberti L, Biondi A, Bonfanti P, Castagnoli R, Delmonte OM, Zhang Y, Snow AL, Holland SM, Biggs C, Moncada-Vélez M, Arias AA, Lorenzo L, Boucherit S, Coulibaly B, Anglicheau D, Planas AM, Haerynck F, Duvlis S, Nussbaum RL, Ozcelik T, Keles S, Bousfiha AA, El Bakkouri J, Ramirez-Santana C, Paul S, Pan-Hammarström Q, Hammarström L, Dupont A, Kurolap A, Metz CN, Aiuti A, Casari G, Lampasona V, Ciceri F, Barreiros LA, Dominguez-Garrido E, Vidigal M, Zatz M, van de Beek D, Sahanic S, Tancevski I, Stepanovskyy Y, Boyarchuk O, Nukui Y, Tsumura M, Vidaur L, Tangye SG, Burrel S, Duffy D, Quintana-Murci L, Klocperk A, Kann NY, Shcherbina A, Lau YL, Leung D, Coulongeat M, Marlet J, Koning R, Reyes LF, Chauvineau-Grenier A, Venet F, Monneret G, Nussenzweig MC, Arrestier R, Boudhabhay I, Baris-Feldman H, Hagin D, Wauters J, Meyts I, Dyer AH, Kennelly SP, Bourke NM, Halwani R, Sharif-Askari NS, Dorgham K, Sallette J, Sedkaoui SM, AlKhater S, Rigo-Bonnin R, Morandeira F, Roussel L, Vinh DC, Ostrowski SR, Condino-Neto A, Prando C, Bonradenko A, Spaan AN, Gilardin L, Fellay J, Lyonnet S, Bilguvar K, Lifton RP, Mane S, HL, CC, CSC, NIRtCG, NCSG, DC, DBDS, SJH, SCIg, FCCSG, ICG, MIC, CCC, AUC1, BI, CHGE, Cc, 3DS, CHC, EdSsg, Anderson MS, Boisson B, Béziat V, Zhang SY, Vandreakos E, Hermine O, Pujol A, Peterson P, Mogensen TH, Rowen L, Mond J, Debette S, de Lamballerie X, Duval X, Mentré F, Zins M, Soler-Palacin P, Colobran R, Gorochov G, Solanich X, Susen S, Martinez-Picado J, Raoult D, Vasse M, Gregersen PK, Piemonti L, Rodríguez-Gallego C, Notarangelo LD, Su HC, Kisand K, Okada S, Puel A, Jouanguy E, Rice CM, Tiberghien P, Zhang Q, Cobat A, Abel L, Casanova JL
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths.
Science Immunology 2021, 6, eabl4340.

Manchon P, Belhadi D, Mentré F, Laouénan C
Evaluation by simulation of clinical trial designs for evaluation of treatment during a viral haemorrhagic fever outbreak.
BMC medical research methodology 2021, 21, 98.

Comets E, Mentré F
Developing Tools to Evaluate Non-linear Mixed Effect Models: 20 Years on the npde Adventure.
The AAPS journal 2021, 23, 75.

Gonçalves A, Maisonnasse P, Donati F, Albert M, Behillil S, Contreras V, Naninck T, Marlin R, Solas C, Pizzorno A, Lemaitre J, Kahlaoui N, Terrier O, Ho Tsong Fang R, Enouf V, Dereuddre-Bosquet N, Brisebarre A, Touret F, Chapon C, Hoen B, Lina B, Rosa Calatrava M, de Lamballerie X, Mentré F, Le Grand R, van der Werf S, Guedj J
SARS-CoV-2 viral dynamics in non-human primates.
PLoS computational biology 2021, 17, e1008785.


Mentré F, Friberg LE, Duffull S, French J, Lauffenburger DA, Li L, Mager DE, Sinha V, Sobie E, Zhao P
Pharmacometrics and Systems Pharmacology 2030.
Clinical Pharmacology and Therapeutics 2020, 107, 76-78.

Eloy P, Solas C, Touret F, Mentré F, Malvy D, de Lamballerie X, Guedj J
Dose rationale for favipiravir use in patients infected with SARS-CoV-2.
Clinical Pharmacology and Therapeutics 2020

Madelain V, Mentré F, Baize S, Anglaret X, Laouénan C, Oestereich L, Nguyen THT, Malvy D, Piorkowski G, Graw F, Günther S, Raoul H, de Lamballerie X, Guedj J
Modeling Favipiravir Antiviral Efficacy Against Emerging Viruses: From Animal Studies to Clinical Trials.
CPT: pharmacometrics & systems pharmacology 2020, 9, 258-271.

Gonçalves A, Bertrand J, Ke R, Comets E, de Lamballerie X, Malvy D, Pizzorno A, Terrier O, Rosa Calatrava M, Mentré F, Smith P, Perelson AS, Guedj J
Timing of Antiviral Treatment Initiation is Critical to Reduce SARS-CoV-2 Viral Load.
CPT: pharmacometrics & systems pharmacology 2020, 9, 509-514.

Seurat J, Girard P, Goteti K, Mentré F
Comparison of Various Phase I Combination Therapy Designs in Oncology for Evaluation of Early Tumor Shrinkage Using Simulations.
CPT: pharmacometrics & systems pharmacology 2020, 9, 686-694.

Madelain V, Duthey A, Mentré F, Jacquot F, Solas C, Lacarelle B, Vallvé A, Barron S, Barrot L, Mundweiler S, Thomas D, Carbonnelle C, Raoul H, de Lamballerie X, Guedj J
Ribavirin does not potentiate favipiravir antiviral activity against Ebola virus in non-human primates.
Antiviral Research 2020, 177, 104758.

Sallard E, Lescure FX, Yazdanpanah Y, Mentre F, Peiffer-Smadja N
Type 1 interferons as a potential treatment against COVID-19.
Antiviral Research 2020, 178, 104791.

Fragkou PC, Belhadi D, Peiffer-Smadja N, Moschopoulos CD, Lescure FX, Janocha H, Karofylakis E, Yazdanpanah Y, Mentré F, Skevaki C, Laouénan C, Tsiodras S, ESGfRV
Review of trials currently testing treatment and prevention of COVID-19.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2020, 26, 988-998.

Wauquier N, Couffignal C, Manchon P, Smith E, Lungay V, Coomber M, Weisenfluh L, Bangura J, Khan SH, Jambai A, Gbakima A, Yun N, Paessler S, Schoepp R, Morse SS, Gonzalez JP, Fair J, Mentré F, Vieillard V
High heart rate at admission as a predictive factor of mortality in hospitalized patients with Lassa fever: An observational cohort study in Sierra Leone.
The Journal of Infection 2020, 80, 671-693.

Lescure FX, Bouadma L, Nguyen D, Parisey M, Wicky PH, Behillil S, Gaymard A, Bouscambert-Duchamp M, Donati F, Le Hingrat Q, Enouf V, Houhou-Fidouh N, Valette M, Mailles A, Lucet JC, Mentre F, Duval X, Descamps D, Malvy D, Timsit JF, Lina B, van-der-Werf S, Yazdanpanah Y
Clinical and virological data of the first cases of COVID-19 in Europe: a case series.
The Lancet. Infectious Diseases 2020, 20, 697-706.

Loingeville F, Nguyen TT, Riviere MK, Mentré F
Robust designs in longitudinal studies accounting for parameter and model uncertainties - application to count data.
Journal of Biopharmaceutical Statistics 2020, 30, 31-45.

Couffignal C, Kolta S, Flamant M, Cazanave C, Haymann JP, Mentré F, Duval X, Leport C, Raffi F, ACACSG
Nevirapine Use Is Associated with Higher Bone Mineral Density in HIV-1 Positive Subjects on Long-Term Antiretroviral Therapy.
AIDS research and human retroviruses 2020, 36, 399-405.

Charpentier C, Peytavin G, Raffi F, Burdet C, Landman R, Lê MP, Katlama C, Collin G, Benalycherif A, Cabie A, Mentré F, Yazdanpanah Y, Descamps D, Joly V
Pharmacovirological analyses of blood and male genital compartment in patients receiving dolutegravir + lamivudine dual therapy as a switch strategy (ANRS 167 LAMIDOL trial).
The Journal of Antimicrobial Chemotherapy 2020, 75, 1611-1617.

de Lastours V, Laouénan C, Royer G, Carbonnelle E, Lepeule R, Esposito-Farèse M, Clermont O, Duval X, Fantin B, Mentré F, Decousser JW, Denamur E, Lefort A
Mortality in Escherichia coli bloodstream infections: antibiotic resistance still does not make it.
The Journal of Antimicrobial Chemotherapy 2020, 75, 2334-2343.

Lê MP, Peiffer-Smadja N, Guedj J, Néant N, Mentré F, Ader F, Yazdanpanah Y, Peytavin G
Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial.
The Journal of Antimicrobial Chemotherapy 2020, 75, 2376-2380.

Mellon G, Hammas K, Burdet C, Duval X, Carette C, El-Helali N, Massias L, Mentré F, Czernichow S, Crémieux AC
Population pharmacokinetics and dosing simulations of amoxicillin in obese adults receiving co-amoxiclav.
The Journal of Antimicrobial Chemotherapy 2020, 75, 3611-3618.

Couffignal C, Amour J, Ait-Hamou N, Cholley B, Fellahi JL, Duval X, Costa De Beauregard Y, Nataf P, Dilly MP, Provenchère S, Montravers P, Mentré F, Longrois D
Timing of β-Blocker Reintroduction and the Occurrence of Postoperative Atrial Fibrillation after Cardiac Surgery: A Prospective Cohort Study.
Anesthesiology 2020, 132, 267-279.

Seurat J, Nguyen TT, Mentré F
Robust designs accounting for model uncertainty in longitudinal studies with binary outcomes.
Statistical Methods in Medical Research 2020, 29, 934-952.

Dodd LE, Follmann D, Wang J, Koenig F, Korn LL, Schoergenhofer C, Proschan M, Hunsberger S, Bonnett T, Makowski M, Belhadi D, Wang Y, Cao B, Mentre F, Jaki T
Endpoints for randomized controlled clinical trials for COVID-19 treatments.
Clinical Trials (London, England) 2020, 17, 472-482.

Massot M, Haenni M, Nguyen TT, Madec JY, Mentré F, Denamur E
Temporal dynamics of the fecal microbiota in veal calves in a 6-month field trial.
Animal Microbiome 2020, 2, 32.

Riglet F, Mentre F, Veyrat-Follet C, Bertrand J
Bayesian Individual Dynamic Predictions with Uncertainty of Longitudinal Biomarkers and Risks of Survival Events in a Joint Modelling Framework: a Comparison Between Stan, Monolix, and NONMEM.
The AAPS journal 2020, 22, 50.

Loingeville F, Bertrand J, Nguyen TT, Sharan S, Feng K, Sun W, Han J, Grosser S, Zhao L, Fang L, Möllenhoff K, Dette H, Mentré F
New Model-Based Bioequivalence Statistical Approaches for Pharmacokinetic Studies with Sparse Sampling.
The AAPS journal 2020, 22, 141.

Gonçalves A, Mentré F, Lemenuel-Diot A, Guedj J
Model Averaging in Viral Dynamic Models.
The AAPS journal 2020, 22, 48.

Malvy D, Taburet AM, de Lamballerie X, Mentre F, Extramiana F
The safety profile of favipiravir should not be the first argument to suspend its evaluation in viral hemorrhagic fevers.
PLoS neglected tropical diseases 2020, 14, e0008259.


Tardivon C, Desmée S, Kerioui M, Bruno R, Wu B, Mentré F, Mercier F, Guedj J
Association Between Tumor Size Kinetics and Survival in Patients With Urothelial Carcinoma Treated With Atezolizumab: Implication for Patient Follow-Up.
Clinical Pharmacology and Therapeutics 2019, 106, 810-820.

Mentré F
CPT: Pharmacometrics & Systems Pharmacology 2.0.
CPT: pharmacometrics & systems pharmacology 2019, 8, 195-196.

Krause A, Kloft C, Huisinga W, Karlsson M, Pinheiro J, Bies R, Rogers J, Mentré F, Musser BJ, ASIGoSaPSIGoSaP(S
Comment on Jaki et al., A proposal for a new PhD level curriculum on quantitative methods for drug development. Pharmaceutical Statistics 17 (5):593-606, Sep/Oct 2018, DOI: 10.1002/pst.1873.
Pharmaceutical Statistics 2019, 18, 278-281.

Couffignal C, Bertrand J, Sportiche S, Jarroir M, El Balkhi S, Djebrani-Oussedik N, Poupon J, Declèves X, Mentré F, Bellivier F
Population pharmacokinetic modeling of sustained release lithium in the serum, erythrocytes and urine of patients with bipolar disorder.
European Journal of Clinical Pharmacology 2019, 75, 519-528.

Berger J, Vigan M, Pereira B, Nguyen TT, Froissart R, Belmatoug N, Dalbiès F, Masseau A, Rose C, Serratrice C, Pers YM, Bertchansky I, Camou F, Bengherbia M, Bourgne C, Caillaud C, Pettazzoni M, Berrahal A, Stirnemann J, Mentré F, Berger MG
Intra-monocyte Pharmacokinetics of Imiglucerase Supports a Possible Personalized Management of Gaucher Disease Type 1.
Clinical Pharmacokinetics 2019, 58, 469-482.

Maataoui N, Mayet A, Duron S, Delacour H, Mentré F, Laouenan C, Desvillechabrol D, Cokelaer T, Meynard JB, Ducher A, Andremont A, Armand-Lefèvre L, Mérens A
High acquisition rate of extended-spectrum β-lactamase-producing Enterobacteriaceae among French military personnel on mission abroad, without evidence of inter-individual transmission.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2019, 25, 631.e1-631.e9.

Bastard JP, Couffignal C, Fellahi S, Bard JM, Mentre F, Salmon D, Katlama C, Raffi F, Leport C, Capeau J, ACACCsg
Diabetes and dyslipidaemia are associated with oxidative stress independently of inflammation in long-term antiretroviral-treated HIV-infected patients.
Diabetes & Metabolism 2019, 45, 573-581.

Joly V, Burdet C, Landman R, Vigan M, Charpentier C, Katlama C, Cabié A, Benalycherif A, Peytavin G, Yeni P, Mentre F, Argoud AL, Amri I, Descamps D, Yazdanpanah Y, LSG
Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL).
The Journal of Antimicrobial Chemotherapy 2019, 74, 739-745.

Burdet C, Nguyen TT, Duval X, Ferreira S, Andremont A, Guedj J, Mentré F, DC1SG
Impact of Antibiotic Gut Exposure on the Temporal Changes in Microbiome Diversity.
Antimicrobial Agents and Chemotherapy 2019, 63, e00820-19.

Saint-Lu N, Burdet C, Sablier-Gallis F, Corbel T, Nevière A, Sayah-Jeanne S, Pulse M, Weiss W, Ferreira S, Andremont A, Mentré F, de Gunzburg J
DAV131A Protects Hamsters from Lethal Clostridioides difficile Infection Induced by Fluoroquinolones.
Antimicrobial Agents and Chemotherapy 2019, 64, e01196-19.

Burdet C, Grall N, Linard M, Bridier-Nahmias A, Benhayoun M, Bourabha K, Magnan M, Clermont O, d'Humières C, Tenaillon O, Denamur E, Massias L, Tubiana S, Alavoine L, Andremont A, Mentré F, Duval X, CG
Ceftriaxone and Cefotaxime Have Similar Effects on the Intestinal Microbiota in Human Volunteers Treated by Standard-Dose Regimens.
Antimicrobial Agents and Chemotherapy 2019, 63, e02244-18.


Beydon N, Nguyen TT, Amsallem F, Denjean A, Fenu G, Seddon P, Mentré F, Alberti C, Lombardi E
Interrupter resistance to measure dose-response to salbutamol in wheezy preschool children.
Pediatric Pulmonology 2018, 53, 1252-1259.

Terranova N, Smith MK, Nordgren R, Comets E, Lavielle M, Harling K, Hooker AC, Sarr C, Mentré F, Yvon F, Swat MJ
The Standard Output: A Tool-Agnostic Modeling Storage Format.
CPT: pharmacometrics & systems pharmacology 2018, 7, 543-546.

Dumont C, Lestini G, Le Nagard H, Mentré F, Comets E, Nguyen TT, PG
PFIM 4.0, an extended R program for design evaluation and optimization in nonlinear mixed-effect models.
Computer Methods and Programs in Biomedicine 2018, 156, 217-229.

Madelain V, Baize S, Jacquot F, Reynard S, Fizet A, Barron S, Solas C, Lacarelle B, Carbonnelle C, Mentré F, Raoul H, de Lamballerie X, Guedj J
Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies.
Nature Communications 2018, 9, 4013.

de Gunzburg J, Ghozlane A, Ducher A, Le Chatelier E, Duval X, Ruppe E, Armand-Lefevre L, Sablier-Gallis F, Burdet C, Alavoine L, Chachaty E, Augustin V, Varastet M, Levenez F, Kennedy S, Pons N, Mentre F, Andremont A
Protection of the Human Gut Microbiome From Antibiotics.
J Infect Dis 2018, 217, 628-636.

Burdet C, Sayah-Jeanne S, Nguyen TT, Hugon P, Sablier-Gallis F, Saint-Lu N, Corbel T, Ferreira S, Pulse M, Weiss W, Andremont A, Mentré F, de Gunzburg J
Antibiotic-Induced Dysbiosis Predicts Mortality in an Animal Model of Clostridium difficile Infection.
Antimicrobial Agents and Chemotherapy 2018, 62, e00925-18.

Burdet C, Loubet P, Le Moing V, Vindrios W, Esposito-Farèse M, Linard M, Ferry T, Massias L, Tattevin P, Wolff M, Vandenesch F, Grall N, Quintin C, Mentré F, Duval X, Lescure FX, Csg
Efficacy of cloxacillin versus cefazolin for methicillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): study protocol for a randomised, controlled, non-inferiority trial.
BMJ open 2018, 8, e023151.

Hilgers RD, Bogdan M, Burman CF, Dette H, Karlsson M, König F, Male C, Mentré F, Molenberghs G, Senn S
Lessons learned from IDeAl - 33 recommendations from the IDeAl-net about design and analysis of small population clinical trials.
Orphanet Journal of Rare Diseases 2018, 13, 77.

Buatois S, Ueckert S, Frey N, Retout S, Mentré F
Comparison of Model Averaging and Model Selection in Dose Finding Trials Analyzed by Nonlinear Mixed Effect Models.
The AAPS journal 2018, 20, 56.

Guedj J, Piorkowski G, Jacquot F, Madelain V, Nguyen THT, Rodallec A, Gunther S, Carbonnelle C, Mentre F, Raoul H, de Lamballerie X
Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques.
PLoS Med 2018, 15, e1002535.


Nguyen TH, Mouksassi MS, Holford N, Al-Huniti N, Freedman I, Hooker AC, John J, Karlsson MO, Mould DR, Perez Ruixo JJ, Plan EL, Savic R, van Hasselt JG, Weber B, Zhou C, Comets E, Mentre F
Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics.
CPT Pharmacometrics Syst Pharmacol 2017, 6, 87-109.

Smith MK, Moodie SL, Bizzotto R, Blaudez E, Borella E, Carrara L, Chan P, Chenel M, Comets E, Gieschke R, Harling K, Harnisch L, Hartung N, Hooker AC, Karlsson MO, Kaye R, Kloft C, Kokash N, Lavielle M, Lestini G, Magni P, Mari A, Mentré F, Muselle C, Nordgren R, Nyberg HB, Parra-Guillén ZP, Pasotti L, Rode-Kristensen N, Sardu ML, Smith GR, Swat MJ, Terranova N, Yngman G, Yvon F, Holford N, Dc
Model Description Language (MDL): A Standard for Modeling and Simulation.
CPT: pharmacometrics & systems pharmacology 2017, 6, 647-650.

Nguyen THT, Nguyen TT, Mentre F
Individual Bayesian Information Matrix for Predicting Estimation Error and Shrinkage of Individual Parameters Accounting for Data Below the Limit of Quantification.
Pharm Res 2017, 34, 2119-2130.

Piorkowski G, Jacquot F, Quérat G, Carbonnelle C, Pannetier D, Mentré F, Raoul H, de Lamballerie X
Implementation of a non-human primate model of Ebola disease: Infection of Mauritian cynomolgus macaques and analysis of virus populations.
Antiviral Research 2017, 140, 95-105.

Ueckert S, Mentre F
A new method for evaluation of the Fisher information matrix for discrete mixed effect models using Monte Carlo sampling and adaptive Gaussian quadrature.
Computational Statistics & Data Analysis 2017, 111, 203–219.

Clermont O, Couffignal C, Blanco J, Mentre F, Picard B, Denamur E
Two levels of specialization in bacteraemic Escherichia coli strains revealed by their comparison with commensal strains.
Epidemiol Infect 2017, 145, 872-882.

Desmée S, Mentré F, Veyrat-Follet C, Sébastien B, Guedj J
Using the SAEM algorithm for mechanistic joint models characterizing the relationship between nonlinear PSA kinetics and survival in prostate cancer patients.
Biometrics 2017, 73, 305-312.

Burdet C, Sayah-Jeanne S, Nguyen TT, Miossec C, Saint-Lu N, Pulse M, Weiss W, Andremont A, Mentré F, de Gunzburg J
Protection of Hamsters from Mortality by Reducing Fecal Moxifloxacin Concentration with DAV131A in a Model of Moxifloxacin-Induced Clostridium difficile Colitis.
Antimicrobial Agents and Chemotherapy 2017, 61, e00543-17.

Madelain V, Guedj J, Mentré F, Nguyen THT, Jacquot F, Oestereich L, Kadota T, Yamada K, Taburet AM, de Lamballerie X, Raoul H
Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses.
Antimicrobial Agents and Chemotherapy 2017, 61, e01305-16.

Massot M, Couffignal C, Clermont O, D'Humières C, Chatel J, Plault N, Andremont A, Caron A, Mentré F, Denamur E
Day-to-Day Dynamics of Commensal Escherichia coli in Zimbabwean Cows Evidence Temporal Fluctuations within a Host-Specific Population Structure.
Applied and Environmental Microbiology 2017, 83, e00659-17.

Desmee S, Mentre F, Veyrat-Follet C, Sebastien B, Guedj J
Nonlinear joint models for individual dynamic prediction of risk of death using Hamiltonian Monte Carlo: application to metastatic prostate cancer.
BMC Med Res Methodol 2017, 17, 105.

Nguyen TH, Guedj J, Anglaret X, Laouenan C, Madelain V, Taburet AM, Baize S, Sissoko D, Pastorino B, Rodallec A, Piorkowski G, Carazo S, Conde MN, Gala JL, Bore JA, Carbonnelle C, Jacquot F, Raoul H, Malvy D, de Lamballerie X, Mentre F
Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted.
PLoS Negl Trop Dis 2017, 11, e0005389.


Lenuzza N, Duval X, Nicolas G, Thévenot E, Job S, Videau O, Narjoz C, Loriot MA, Beaune P, Becquemont L, Mentré F, Funck-Brentano C, Alavoine L, Arnaud P, Delaforge M, Bénech H
Safety and pharmacokinetics of the CIME combination of drugs and their metabolites after a single oral dosing in healthy volunteers.
European Journal of Drug Metabolism and Pharmacokinetics 2016, 41, 125–138.

Madelain V, Nguyen TH, Olivo A, de Lamballerie X, Guedj J, Taburet AM, Mentre F
Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials.
Clin Pharmacokinet 2016, 55, 907-23.

Dumont C, Chenel M, Mentre F
Two-stage Adaptive Designs in Nonlinear Mixed Effects Models: Application to Pharmacokinetics in Children.
Communications in Statistics-Simulation and Computation 2016, 45, 1511–1525.

Riviere MK, Ueckert S, Mentre F
An MCMC method for the evaluation of the Fisher information matrix for non-linear mixed effect models.
Biostatistics 2016, 17, 737-50.

Massot M, Daubie AS, Clermont O, Jaureguy F, Couffignal C, Dahbi G, Mora A, Blanco J, Branger C, Mentre F, Eddi A, Picard B, Denamur E, The Coliville G
Phylogenetic, virulence and antibiotic resistance characteristics of commensal strain populations of Escherichia coli from community subjects in the Paris area in 2010 and evolution over 30 years.
Microbiology 2016, 162, 642-50.

Abramowitz L, Benabderrahmane D, Walker F, Yazdapanah Y, Yeni P, Rioux C, Bouscarat F, Lafferre E, Mentre F, Duval X
Determinants of macroscopic anal cancer and precancerous lesions in 1206 HIV-infected screened patients.
Colorectal Dis 2016, 18, 997-1004.

Casalino E, Etienne A, Mentre F, Houze S
Hospitalization and ambulatory care in imported-malaria: evaluation of trends and impact on mortality. A prospective multicentric 14-year observational study.
Malar J 2016, 15, 312.

Lestini G, Mentre F, Magni P
Optimal Design for Informative Protocols in Xenograft Tumor Growth Inhibition Experiments in Mice.
AAPS J 2016, 18, 1233-43.

Sissoko D, Laouenan C, Folkesson E, M'Lebing AB, Beavogui AH, Baize S, Camara AM, Maes P, Shepherd S, Danel C, Carazo S, Conde MN, Gala JL, Colin G, Savini H, Bore JA, Le Marcis F, Koundouno FR, Petitjean F, Lamah MC, Diederich S, Tounkara A, Poelart G, Berbain E, Dindart JM, Duraffour S, Lefevre A, Leno T, Peyrouset O, Irenge L, Bangoura N, Palich R, Hinzmann J, Kraus A, Barry TS, Berette S, Bongono A, Camara MS, Chanfreau Munoz V, Doumbouya L, Souley Harouna n, Kighoma PM, Koundouno FR, Réné Lolamou n, Loua CM, Massala V, Moumouni K, Provost C, Samake N, Sekou C, Soumah A, Arnould I, Komano MS, Gustin L, Berutto C, Camara D, Camara FS, Colpaert J, Delamou L, Jansson L, Kourouma E, Loua M, Malme K, Manfrin E, Maomou A, Milinouno A, Ombelet S, Sidiboun AY, Verreckt I, Yombouno P, Bocquin A, Carbonnelle C, Carmoi T, Frange P, Mely S, Nguyen VK, Pannetier D, Taburet AM, Treluyer JM, Kolie J, Moh R, Gonzalez MC, Kuisma E, Liedigk B, Ngabo D, Rudolf M, Thom R, Kerber R, Gabriel M, Di Caro A, Wölfel R, Badir J, Bentahir M, Deccache Y, Dumont C, Durant JF, El Bakkouri K, Gasasira Uwamahoro M, Smits B, Toufik N, Van Cauwenberghe S, Ezzedine K, D'Ortenzio E, Dortenzio E, Pizarro L, Etienne A, Guedj J, Fizet A, Barte de Sainte Fare E, Murgue B, Tran-Minh T, Rapp C, Piguet P, Poncin M, Draguez B, Allaford Duverger T, Barbe S, Baret G, Defourny I, Carroll M, Raoul H, Augier A, Eholie SP, Yazdanpanah Y, Levy-Marchal C, Antierrens A, Van Herp M, Günther S, de Lamballerie X, Keïta S, Mentre F, Anglaret X, Malvy D, JSG
Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.
PLoS medicine 2016, 13, e1001967.


Swat MJ, Moodie S, Wimalaratne SM, Kristensen NR, Lavielle M, Mari A, Magni P, Smith MK, Bizzotto R, Pasotti L, Mezzalana E, Comets E, Sarr C, Terranova N, Blaudez E, Chan P, Chard J, Chatel K, Chenel M, Edwards D, Franklin C, Giorgino T, Glont M, Girard P, Grenon P, Harling K, Hooker AC, Kaye R, Keizer R, Kloft C, Kok JN, Kokash N, Laibe C, Laveille C, Lestini G, Mentré F, Munafo A, Nordgren R, Nyberg HB, Parra-Guillen ZP, Plan E, Ribba B, Smith G, Trocóniz IF, Yvon F, Milligan PA, Harnisch L, Karlsson M, Hermjakob H, Le Novère N
Pharmacometrics Markup Language (PharmML): Opening New Perspectives for Model Exchange in Drug Development.
CPT: pharmacometrics & systems pharmacology 2015, 4, 316–319.

Laouenan C, Guedj J, Peytavin G, Nguyen TT, Lapalus M, Khelifa-Mouri F, Boyer N, Zoulim F, Serfaty L, Bronowicki JP, Martinot-Peignoux M, Lada O, Asselah T, Dorival C, Hezode C, Carrat F, Nicot F, Marcellin P, Mentre F
A Model-Based Illustrative Exploratory Approach to Optimize the Dosing of Peg-IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple Therapy.
CPT Pharmacometrics Syst Pharmacol 2015, 4, e00008.

Burdet C, Pajot O, Couffignal C, Armand-Lefèvre L, Foucrier A, Laouénan C, Wolff M, Massias L, Mentré F
Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia.
European Journal of Clinical Pharmacology 2015, 71, 75–83.

Lestini G, Dumont C, Mentré F
Influence of the Size of Cohorts in Adaptive Design for Nonlinear Mixed Effects Models: An Evaluation by Simulation for a Pharmacokinetic and Pharmacodynamic Model for a Biomarker in Oncology.
Pharmaceutical Research 2015, 32, 3159–3169.

Madelain V, Oestereich L, Graw F, Nguyen THT, de Lamballerie X, Mentré F, Günther S, Guedj J
Ebola virus dynamics in mice treated with favipiravir.
Antiviral Research 2015, 123, 70–77.

Couffignal C, Desgrandchamps F, Mongiat-Artus P, Ravery V, Ouzaid I, Roupret M, Phe V, Ciofu C, Tubach F, Mentre F, Cussenot O, Grandchamp B
The Diagnostic and Prognostic Performance of Urinary FGFR3 Mutation Analysis in Bladder Cancer Surveillance: A Prospective Multicenter Study.
Urology 2015, 86, 1185-1190.

Bouazza N, Treluyer JM, Foissac F, Mentré F, Taburet AM, Guedj J, Anglaret X, de Lamballerie X, Keïta S, Malvy D, Frange P
Favipiravir for children with Ebola.
Lancet (London, England) 2015, 385, 603–604.

Mentré F, Taburet AM, Guedj J, Anglaret X, Keïta S, de Lamballerie X, Malvy D
Dose regimen of favipiravir for Ebola virus disease.
The Lancet. Infectious Diseases 2015, 15, 150–151.

Yazdanpanah Y, Horby P, van Griensven J, Mentre F, Nguyen VK, Malvy JMD, Dunning J, Sissoko D, Delfraissy JF, Levy Y
Drug assessment in the Ebola virus disease epidemic in west Africa.
The Lancet. Infectious Diseases 2015, 15, 1258.

Maubec E, Laouénan C, Deschamps L, Nguyen VT, Scheer-Senyarich I, Wackenheim-Jacobs AC, Steff M, Duhamel S, Tubiana S, Brahimi N, Leclerc-Mercier S, Crickx B, Perret C, Aractingi S, Escoubet B, Duval X, Arnaud P, Jaisser F, Mentré F, Farman N
Topical Mineralocorticoid Receptor Blockade Limits Glucocorticoid-Induced Epidermal Atrophy in Human Skin.
The Journal of Investigative Dermatology 2015, 135, 1781–1789.

Soubirou JF, Rossi B, Couffignal C, Ruppé E, Chau F, Massias L, Lepeule R, Mentre F, Fantin B
Activity of temocillin in a murine model of urinary tract infection due to Escherichia coli producing or not producing the ESBL CTX-M-15.
The Journal of Antimicrobial Chemotherapy 2015, 70, 1466–1472.

Pajot O, Burdet C, Couffignal C, Massias L, Armand-Lefevre L, Foucrier A, Da Silva D, Lasocki S, Laouénan C, Mentec H, Mentré F, Wolff M
Impact of imipenem and amikacin pharmacokinetic/pharmacodynamic parameters on microbiological outcome of Gram-negative bacilli ventilator-associated pneumonia.
The Journal of Antimicrobial Chemotherapy 2015, 70, 1487–1494.

Guglielminotti J, Grillot N, Paule M, Mentré F, Servin F, Montravers P, Longrois D
Prediction of movement to surgical stimulation by the pupillary dilatation reflex amplitude evoked by a standardized noxious test.
Anesthesiology 2015, 122, 985–993.

Nyberg J, Bazzoli C, Ogungbenro K, Aliev A, Leonov S, Duffull S, Hooker AC, Mentré F
Methods and software tools for design evaluation in population pharmacokinetics-pharmacodynamics studies.
British Journal of Clinical Pharmacology 2015, 79, 6–17.

Desmée S, Mentré F, Veyrat-Follet C, Guedj J
Nonlinear Mixed-effect Models for Prostate-specific Antigen Kinetics and Link with Survival in the Context of Metastatic Prostate Cancer: A Comparison by Simulation of Two-stage and Joint Approaches.
The AAPS journal 2015, 17, 691–699.

Guglielminotti J, Dechartres A, Mentré F, Montravers P, Longrois D, Laouénan C
Reporting and Methodology of Multivariable Analyses in Prognostic Observational Studies Published in 4 Anesthesiology Journals: A Methodological Descriptive Review.
Anesthesia and Analgesia 2015, 121, 1011–1029.


Thai HT, Mentré F, Holford NHG, Veyrat-Follet C, Comets E
Evaluation of bootstrap methods for estimating uncertainty of parameters in nonlinear mixed-effects models: a simulation study in population pharmacokinetics.
Journal of Pharmacokinetics and Pharmacodynamics 2014, 41, 15–33.

Bauer R, Mentré F, Kaddouri H, Le Bras J, Le Nagard H
Benefits of a new Metropolis-Hasting based algorithm, in non-linear regression for estimation of ex vivo antimalarial sensitivity in patients infected with two strains.
Computers in Biology and Medicine 2014, 55, 16–25.

Nguyen TT, Mentre F
Evaluation of the Fisher information matrix in nonlinear mixed effect models using adaptive Gaussian quadrature.
Computational Statistics & Data Analysis 2014, 80, 57–69.

Roubaud Baudron C, Panhard X, Clermont O, Mentré F, Fantin B, Denamur E, Lefort A, CG
Escherichia coli bacteraemia in adults: age-related differences in clinical and bacteriological characteristics, and outcome.
Epidemiology and Infection 2014, 142, 2672-2683.

Ribba B, Holford N, Mentré F
The use of model-based tumor-size metrics to predict survival.
Clinical Pharmacology and Therapeutics 2014, 96, 133–135.

Nguyen THT, Mentré F, Levi M, Yu J, Guedj J
A pharmacokinetic-viral kinetic model describes the effect of alisporivir as monotherapy or in combination with peg-IFN on hepatitis C virologic response.
Clinical Pharmacology and Therapeutics 2014, 96, 599–608.

Bruno R, Mentré F, Tannenbaum S, Wang Y, Corrigan B, Mager DE
The ISoP Standards and Best Practices Committee.
Clinical Pharmacology and Therapeutics 2014, 95, 581–582.

Combes FP, Retout S, Frey N, Mentré F
Powers of the likelihood ratio test and the correlation test using empirical bayes estimates for various shrinkages in population pharmacokinetics.
CPT: pharmacometrics & systems pharmacology 2014, 3, e109.

Mentré F
Lewis Sheiner ISoP/UCSF Lecturer Award: From Drug Use to Statistical Models and Vice Versa.
CPT: pharmacometrics & systems pharmacology 2014, 3, e154.

Dumont C, Chenel M, Mentré F
Influence of covariance between random effects in design for nonlinear mixed-effect models with an illustration in pediatric pharmacokinetics.
Journal of Biopharmaceutical Statistics 2014, 24, 471–492.

Chow SC, Endrenyi L, Lachenbruch PA, Mentré F
Scientific factors and current issues in biosimilar studies.
Journal of Biopharmaceutical Statistics 2014, 24, 1138–1153.

Gelly J, Le Bel J, Aubin-Auger I, Mercier A, Youssef E, Mentre F, Nougairede M, Letrilliart L, Duval X, Esg
Profile of French general practitioners providing opportunistic primary preventive care–an observational cross-sectional multicentre study.
Family Practice 2014, 31, 445–452.

Bertrand J, Verstuyft C, Chou M, Borand L, Chea P, Nay KH, Blanc FX, Mentré F, Taburet AM, C(1CKSG
Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia.
The Journal of Infectious Diseases 2014, 209, 399–408.

Burdet C, Clermont O, Bonacorsi S, Laouénan C, Bingen E, Aujard Y, Mentré F, Lefort A, Denamur E, CG
Escherichia coli bacteremia in children: age and portal of entry are the main predictors of severity.
The Pediatric Infectious Disease Journal 2014, 33, 872–879.

Surgers L, Bleibtreu A, Burdet C, Clermont O, Laouénan C, Lefort A, Mentré F, Carbonne B, Bingen E, Meynard JL, Denamur E, CG
Escherichia coli bacteraemia in pregnant women is life-threatening for foetuses.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2014, 20, O1035–1041.

Couffignal C, Pajot O, Laouénan C, Burdet C, Foucrier A, Wolff M, Armand-Lefevre L, Mentré F, Massias L
Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimens.
British Journal of Clinical Pharmacology 2014, 78, 1022–1034.

Bourgeois-Nicolaos N, Nguyen TT, Defrance G, Massias L, Alavoine L, Lefort A, Noel V, Senneville E, Doucet-Populaire F, Mentré F, Andremont A, Duval X
The emergence of linezolid resistance among Enterococci in intestinal microbiota of treated patients is unrelated to individual pharmacokinetic characteristics.
Antimicrobial Agents and Chemotherapy 2014, 58, 2681–2687.

Laouénan C, Marcellin P, Lapalus M, Khelifa-Mouri F, Boyer N, Zoulim F, Serfaty L, Bronowicki JP, Martinot-Peignoux M, Lada O, Asselah T, Dorival C, Hézode C, Carrat F, Nicot F, Peytavin G, Mentré F, Guedj J
Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patients.
Antimicrobial Agents and Chemotherapy 2014, 58, 5332-5341.

Vigan M, Stirnemann J, Caillaud C, Froissart R, Boutten A, Fantin B, Belmatoug N, Mentré F
Modeling changes in biomarkers in Gaucher disease patients receiving enzyme replacement therapy using a pathophysiological model.
Orphanet Journal of Rare Diseases 2014, 9, 95.

Vigan M, Stirnemann J, Mentré F
Evaluation of estimation methods and power of tests of discrete covariates in repeated time-to-event parametric models: application to Gaucher patients treated by imiglucerase.
The AAPS journal 2014, 16, 415–423.

Nguyen TT, Guedj J, Chachaty E, de Gunzburg J, Andremont A, Mentré F
Mathematical modeling of bacterial kinetics to predict the impact of antibiotic colonic exposure and treatment duration on the amount of resistant enterobacteria excreted.
PLoS computational biology 2014, 10, e1003840.

Konofal E, Zhao W, Laouénan C, Lecendreux M, Kaguelidou F, Benadjaoud L, Mentré F, Jacqz-Aigrain E
Pilot Phase II study of mazindol in children with attention deficit/hyperactivity disorder.
Drug Design, Development and Therapy 2014, 8, 2321–2332.


Thai HT, Mentré F, Holford NHG, Veyrat-Follet C, Comets E
A comparison of bootstrap approaches for estimating uncertainty of parameters in linear mixed-effects models.
Pharmaceutical Statistics 2013, 12, 129–140.

Thai HT, Veyrat-Follet C, Mentré F, Comets E
Population pharmacokinetic analysis of free and bound aflibercept in patients with advanced solid tumors.
Cancer Chemotherapy and Pharmacology 2013, 72, 167–180.

Combes FP, Retout S, Frey N, Mentré F
Prediction of shrinkage of individual parameters using the bayesian information matrix in non-linear mixed effect models with evaluation in pharmacokinetics.
Pharmaceutical Research 2013, 30, 2355–2367.

Dumont C, Mentré F, Gaynor C, Brendel K, Gesson C, Chenel M
Optimal sampling times for a drug and its metabolite using SIMCYP(®) simulations as prior information.
Clinical Pharmacokinetics 2013, 52, 43–57.

Gelly J, Mentre F, Nougairede M, Duval X
Preventive services recommendations for adults in primary care settings: agreement between Canada, France and the USA–a systematic review.
Preventive Medicine 2013, 57, 3–11.

Séroussi B, Laouénan C, Gligorov J, Uzan S, Mentré F, Bouaud J
Which breast cancer decisions remain non-compliant with guidelines despite the use of computerised decision support?.
British Journal of Cancer 2013, 109, 1147–1156.

Mentré F, Chenel M, Comets E, Grevel J, Hooker A, Karlsson MO, Lavielle M, Gueorguieva I
Current Use and Developments Needed for Optimal Design in Pharmacometrics: A Study Performed Among DDMoRe's European Federation of Pharmaceutical Industries and Associations Members.
CPT: pharmacometrics & systems pharmacology 2013, 2, e46.

Nguyen THT, Guedj J, Yu J, Levi M, Mentré F
Influence of a priori Information, Designs, and Undetectable Data on Individual Parameters Estimation and Prediction of Hepatitis C Treatment Outcome.
CPT: pharmacometrics & systems pharmacology 2013, 2, e56.

Karlsson MO, Mentré F
Best practices in population modeling should always be evolving.
CPT: pharmacometrics & systems pharmacology 2013, 2, e52.

Guglielminotti J, Mentré F, Bedairia E, Montravers P, Longrois D
Development and evaluation of a score to predict difficult epidural placement during labor.
Regional Anesthesia and Pain Medicine 2013, 38, 233–238.

Blanchon T, Mentré F, Charlois-Ou C, Dornic Q, Mosnier A, Bouscambert M, Carrat F, Duval X, Enouf V, Leport C, BSG
Factors associated with clinical and virological response in patients treated with oseltamivir or zanamivir for influenza A during the 2008-2009 winter.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2013, 19, 196–203.

Woodrow CJ, Dahlström S, Cooksey R, Flegg JA, Le Nagard H, Mentré F, Murillo C, Ménard D, Nosten F, Sriprawat K, Musset L, Quashie NB, Lim P, Fairhurst RM, Nsobya SL, Sinou V, Noedl H, Pradines B, Johnson JD, Guerin PJ, Sibley CH, Le Bras J
High-throughput analysis of antimalarial susceptibility data by the WorldWide Antimalarial Resistance Network (WWARN) in vitro analysis and reporting tool.
Antimicrobial Agents and Chemotherapy 2013, 57, 3121–3130.

Parienti JJ, Barrail-Tran A, Duval X, Nembot G, Descamps D, Vigan M, Vrijens B, Panhard X, Taburet AM, Mentre F, Goujard C
Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial.
Antimicrob Agents Chemother 2013, 57, 2265-71.

Escoubet B, Couffignal C, Laisy JP, Mangin L, Chillon S, Laouénan C, Serfaty JM, Jeunemaitre X, Mentré F, Zennaro MC
Cardiovascular effects of aldosterone: insight from adult carriers of mineralocorticoid receptor mutations.
Circulation. Cardiovascular Genetics 2013, 6, 381–390.

Laouénan C, Guedj J, Mentré F
Clinical trial simulation to evaluate power to compare the antiviral effectiveness of two hepatitis C protease inhibitors using nonlinear mixed effect models: a viral kinetic approach.
BMC medical research methodology 2013, 13, 60.

Guglielminotti J, Mentré F, Gaillard J, Ghalayini M, Montravers P, Longrois D
Assessment of pain during labor with pupillometry: a prospective observational study.
Anesthesia and Analgesia 2013, 116, 1057–1062.

Abgrall S, Le Bel J, Lele N, Laouénan C, Eychenne N, Mentré F, Peytavin G, Bouchaud O, VSG
Lack of effect of doxycycline on trough concentrations of protease inhibitors or non-nucleoside reverse transcriptase inhibitors in HIV-infected patients.
HIV clinical trials 2013, 14, 313-318.

Nicolas-Chanoine MH, Robert J, Vigan M, Laouenan C, Brisse S, Mentre F, Jarlier V
Different factors associated with CTX-M-producing ST131 and non-ST131 Escherichia coli clinical isolates.
PLoS One 2013, 8, e72191.


Nguyen TT, Bazzoli C, Mentré F
Design evaluation and optimisation in crossover pharmacokinetic studies analysed by nonlinear mixed effects models.
Statistics in Medicine 2012, 31, 1043–1058.

Nguyen THT, Comets E, Mentré F
Extension of NPDE for evaluation of nonlinear mixed effect models in presence of data below the quantification limit with applications to HIV dynamic model.
Journal of Pharmacokinetics and Pharmacodynamics 2012, 39, 499–518.

Ajzenberg N, Ducrocq G, Farnoud R, Huisse MG, Alavoine L, Duval X, Mentré F, Steg PG
Recurrent acute coronary syndromes are associated with increased shear induced platelet aggregation. A case-control study.
International Journal of Cardiology 2012, 155, 313–314.

Guglielminotti J, Dehoux M, Mentré F, Bedairia E, Montravers P, Desmonts JM, Longrois D
Assessment of salivary amylase as a stress biomarker in pregnant patients.
International Journal of Obstetric Anesthesia 2012, 21, 35–39.

Dubois A, Gsteiger S, Balser S, Pigeolet E, Steimer JL, Pillai G, Mentré F
Pharmacokinetic similarity of biologics: analysis using nonlinear mixed-effects modeling.
Clinical Pharmacology and Therapeutics 2012, 91, 234–242.

Comets E, Diquet B, Legrain S, Huisse MG, Godon A, Bruhat C, Chauveheid MP, Delpierre S, Duval X, Berrut G, Verstuyft C, Aumont MC, Mentré F
Pharmacokinetic and pharmacodynamic variability of fluindione in octogenarians.
Clinical Pharmacology and Therapeutics 2012, 91, 777–786.

Savic RM, Barrail-Tran A, Duval X, Nembot G, Panhard X, Descamps D, Verstuyft C, Vrijens B, Taburet AM, Goujard C, Mentré F, A13SG
Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.
Clinical Pharmacology and Therapeutics 2012, 92, 575-583.

Charpentier C, Landman R, Laouénan C, Joly V, Hamet G, Damond F, Brun-Vézinet F, Mentré F, Descamps D, Yeni P
Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors and virological outcome.
The Journal of Antimicrobial Chemotherapy 2012, 67, 2231-2235.

Quesnel C, Piednoir P, Gelly J, Nardelli L, Garnier M, Leçon V, Lasocki S, Bouadma L, Philip I, Elbim C, Mentré F, Soler P, Crestani B, Dehoux M
Alveolar fibrocyte percentage is an independent predictor of poor outcome in patients with acute lung injury.
Critical Care Medicine 2012, 40, 21–28.

Bertrand J, Chou M, Richardson DM, Verstuyft C, Leger PD, Mentré F, Taburet AM, Haas DW, A1SG
Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians.
Pharmacogenetics and Genomics 2012, 22, 868–876.

Bertrand J, Comets E, Chenel M, Mentré F
Some alternatives to asymptotic tests for the analysis of pharmacogenetic data using nonlinear mixed effects models.
Biometrics 2012, 68, 146–155.

Nguyen TT, Chachaty E, Huy C, Cambier C, de Gunzburg J, Mentré F, Andremont A
Correlation between fecal concentrations of ciprofloxacin and fecal counts of resistant Enterobacteriaceae in piglets treated with ciprofloxacin: toward new means to control the spread of resistance?.
Antimicrobial Agents and Chemotherapy 2012, 56, 4973–4975.

Brisse S, Diancourt L, Laouénan C, Vigan M, Caro V, Arlet G, Drieux L, Leflon-Guibout V, Mentré F, Jarlier V, Nicolas-Chanoine MH, CβSG
Phylogenetic distribution of CTX-M- and non-extended-spectrum-β-lactamase-producing Escherichia coli isolates: group B2 isolates, except clone ST131, rarely produce CTX-M enzymes.
Journal of Clinical Microbiology 2012, 50, 2974–2981.

Bouleti C, Iung B, Laouénan C, Himbert D, Brochet E, Messika-Zeitoun D, Détaint D, Garbarz E, Cormier B, Michel PL, Mentré F, Vahanian A
Late results of percutaneous mitral commissurotomy up to 20 years: development and validation of a risk score predicting late functional results from a series of 912 patients.
Circulation 2012, 125, 2119–2127.

Crestani B, Chapron J, Wallaert B, Bergot E, Delaval P, Israel-Biet D, Lacronique J, Monnet I, Reynaud-Gaubert M, Tazi A, Lebtahi R, Debray MP, Brauner M, Dehoux M, Dornic Q, Aubier M, Mentré F, Duval X
Octreotide treatment of idiopathic pulmonary fibrosis: a proof-of-concept study.
The European Respiratory Journal 2012, 39, 772–775.

Stirnemann J, Vigan M, Hamroun D, Heraoui D, Rossi-Semerano L, Berger MG, Rose C, Camou F, de Roux-Serratrice C, Grosbois B, Kaminsky P, Robert A, Caillaud C, Froissart R, Levade T, Masseau A, Mignot C, Sedel F, Dobbelaere D, Vanier MT, Valayanopoulos V, Fain O, Fantin B, de Villemeur TB, Mentré F, Belmatoug N
The French Gaucher's disease registry: clinical characteristics, complications and treatment of 562 patients.
Orphanet Journal of Rare Diseases 2012, 7, 77.

Plan EL, Maloney A, Mentré F, Karlsson MO, Bertrand J
Performance comparison of various maximum likelihood nonlinear mixed-effects estimation methods for dose-response models.
The AAPS journal 2012, 14, 420–432.

Nicolas-Chanoine MH, Jarlier V, Robert J, Arlet G, Drieux L, Leflon-Guibout V, Laouénan C, Larroque B, Caro V, Mentré F, GCβ
Patient's origin and lifestyle associated with CTX-M-producing Escherichia coli: a case-control-control study.
PloS One 2012, 7, e30498.

Lucet JC, Laouenan C, Chelius G, Veziris N, Lepelletier D, Friggeri A, Abiteboul D, Bouvet E, Mentre F, Fleury E
Electronic sensors for assessing interactions between healthcare workers and patients under airborne precautions.
PloS One 2012, 7, e37893.

Carrat F, Duval X, Tubach F, Mosnier A, Van der Werf S, Tibi A, Blanchon T, Leport C, Flahault A, Mentré F, Bsg
Effect of oseltamivir, zanamivir or oseltamivir-zanamivir combination treatments on transmission of influenza in households.
Antiviral Therapy 2012, 17, 1085–1090.

Séroussi B, Soulet A, Messai N, Laouénan C, Mentré F, Bouaud J
Patient clinical profiles associated with physician non-compliance despite the use of a guideline-based decision support system: a case study with OncoDoc2 using data mining techniques.
AMIA ... Annual Symposium proceedings / AMIA Symposium. AMIA Symposium 2012, 2012, 828–837.


Guedj J, Bazzoli C, Neumann AU, Mentré F
Design evaluation and optimization for models of hepatitis C viral dynamics.
Statistics in Medicine 2011, 30, 1045-1056.

Dubois A, Lavielle M, Gsteiger S, Pigeolet E, Mentré F
Model-based analyses of bioequivalence crossover trials using the stochastic approximation expectation maximisation algorithm.
Statistics in Medicine 2011, 30, 2582-2600.

Stirnemann J, Boutten A, Vincent C, Mekinian A, Heraoui D, Fantin B, Fain O, Mentré F, Belmatoug N
Impact of imiglucerase on the serum glycosylated-ferritin level in Gaucher disease.
Blood Cells, Molecules & Diseases 2011, 46, 34-38.

Le Nagard H, Vincent C, Mentré F, Le Bras J
Online analysis of in vitro resistance to antimalarial drugs through nonlinear regression.
Computer Methods and Programs in Biomedicine 2011, 104, 10-18.

Friggeri A, Chelius G, Fleury E, Fraboulet A, Mentré F, Lucet J
Reconstructing social interactions using an unreliable wireless sensor network.
Computer Communications 2011, 34, 609-618.

Pelletier AL, Stefanescu C, Vincent C, Etienney I, Mentré F, Soulé JC
Is the length of postoperative recurrence on the neo ileum terminal ileum predictable in Crohn's disease?.
Journal of Crohn's & Colitis 2011, 5, 24-27.

Thai HT, Veyrat-Follet C, Vivier N, Dubruc C, Sanderink G, Mentré F, Comets E
A mechanism-based model for the population pharmacokinetics of free and bound aflibercept in healthy subjects.
British Journal of Clinical Pharmacology 2011, 72, 402-414.

Courpon-Claudinon A, Lefort A, Panhard X, Clermont O, Dornic Q, Fantin B, Mentré F, Wolff M, Denamur E, Branger C, CG
Bacteraemia caused by third-generation cephalosporin-resistant Escherichia coli in France: prevalence, molecular epidemiology and clinical features.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2011, 17, 557-565.

Bonnet-Zamponi D, Aumont MC, Comets E, Bruhat C, Chauveheid MP, Duval X, Huisse MG, Diquet B, Berrut G, Mentre F, Delpierre S, Legrain S
Heparin bridging therapy and bleeding events in octogenarian inpatients with atrial fibrillation starting anticoagulation: results of an ancillary study.
Journal of the American Geriatrics Society 2011, 59, 2174-2178.

Lavielle M, Samson A, Karina Fermin A, Mentré F
Maximum likelihood estimation of long-term HIV dynamic models and antiviral response.
Biometrics 2011, 67, 250-259.

Bazzoli C, Bénech H, Rey E, Retout S, Salmon D, Duval X, Tréluyer JM, Mentré F, CA1SG
Joint population pharmacokinetic analysis of zidovudine, lamivudine, and their active intracellular metabolites in HIV patients.
Antimicrobial Agents and Chemotherapy 2011, 55, 3423-3431.

Lefort A, Panhard X, Clermont O, Woerther PL, Branger C, Mentré F, Fantin B, Wolff M, Denamur E, CG
Host factors and portal of entry outweigh bacterial determinants to predict the severity of Escherichia coli bacteremia.
Journal of Clinical Microbiology 2011, 49, 777-783.

Maubec E, Petrow P, Scheer-Senyarich I, Duvillard P, Lacroix L, Gelly J, Certain A, Duval X, Crickx B, Buffard V, Basset-Seguin N, Saez P, Duval-Modeste AB, Adamski H, Mansard S, Grange F, Dompmartin A, Faivre S, Mentré F, Avril MF
Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin.
Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2011, 29, 3419-3426.

Savic RM, Mentré F, Lavielle M
Implementation and evaluation of the SAEM algorithm for longitudinal ordered categorical data with an illustration in pharmacokinetics-pharmacodynamics.
The AAPS journal 2011, 13, 44-53.

Bertrand J, Laffont CM, Mentré F, Chenel M, Comets E
Development of a complex parent-metabolite joint population pharmacokinetic model.
The AAPS journal 2011, 13, 390-404.


Brendel K, Comets E, Laffont C, Mentré F
Evaluation of different tests based on observations for external model evaluation of population analyses.
Journal of Pharmacokinetics and Pharmacodynamics 2010, 37, 49-65.

Dubois A, Gsteiger S, Pigeolet E, Mentré F
Bioequivalence tests based on individual estimates using non-compartmental or model-based analyses: evaluation of estimates of sample means and type I error for different designs.
Pharmaceutical Research 2010, 27, 92-104.

Bazzoli C, Retout S, Mentré F
Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0.
Computer Methods and Programs in Biomedicine 2010, 98, 55-65.

Chou M, Bertrand J, Segeral O, Verstuyft C, Borand L, Comets E, Le Tiec C, Becquemont L, Ouk V, Mentre F, Taburet AM
Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients.
Antimicrobial Agents and Chemotherapy 2010, 54, 4432-4439.

Barrail-Tran A, Mentré F, Cosson C, Piketty C, Chazallon C, Gérard L, Girard PM, Taburet AM
Influence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 trial.
Antimicrobial Agents and Chemotherapy 2010, 54, 614-619.

Stirnemann J, Belmatoug N, Vincent C, Fain O, Fantin B, Mentré F
Bone events and evolution of biologic markers in Gaucher disease before and during treatment.
Arthritis Research & Therapy 2010, 12, R156.

Duval X, van der Werf S, Blanchon T, Mosnier A, Bouscambert-Duchamp M, Tibi A, Enouf V, Charlois-Ou C, Vincent C, Andreoletti L, Tubach F, Lina B, Mentré F, Leport C, BSG
Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial.
PLoS medicine 2010, 7, e1000362.

Comets E, Brendel K, Mentré F
Model evaluation in nonlinear mixed effect models, with applications to pharmacokinetics.
Journal de la Société Française de Statistique 2010, 151, 106-128.

Bazzoli C, Jullien V, Le Tiec C, Rey E, Mentre F, Taburet AM
Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.
Clinical Pharmacokinetics 2010, 49, 17-45.


Lucet JC, Paoletti X, Demontpion C, Degrave M, Vanjak D, Vincent C, Andremont A, Jarlier V, Mentré F, Nicolas-Chanoine MH, SaRalMeHAD(HSG
Carriage of methicillin-resistant Staphylococcus aureus in home care settings: prevalence, duration, and transmission to household members.
Archives of Internal Medicine 2009, 169, 1372-1378.

Bazzoli C, Retout S, Mentré F
Fisher information matrix for nonlinear mixed effects multiple response models: evaluation of the appropriateness of the first order linearization using a pharmacokinetic/pharmacodynamic model.
Statistics in Medicine 2009, 28, 1940-1956.

Bertrand J, Treluyer JM, Panhard X, Tran A, Auleley S, Rey E, Salmon-Céron D, Duval X, Mentré F, CA1SG
Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART.
European Journal of Clinical Pharmacology 2009, 65, 667-678.

Bertrand J, Comets E, Laffont CM, Chenel M, Mentré F
Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm.
Journal of Pharmacokinetics and Pharmacodynamics 2009, 36, 317-339.

Aparicio T, Navazesh A, Boutron I, Bouarioua N, Chosidow D, Mion M, Choudat L, Sobhani I, Mentré F, Soulé JC
Half of elderly patients routinely treated for colorectal cancer receive a sub-standard treatment.
Critical Reviews in Oncology/Hematology 2009, 71, 249-257.

Retout S, Comets E, Bazzoli C, Mentré F
Design Optimization in Nonlinear Mixed Effects Models Using Cost Functions: Application to a Joint Model of Infliximab and Methotrexate Pharmacokinetics.
Communications in Statistics - Theory and Methods 2009, 38, 3351-3368.

Fantin B, Duval X, Massias L, Alavoine L, Chau F, Retout S, Andremont A, Mentré F
Ciprofloxacin dosage and emergence of resistance in human commensal bacteria.
The Journal of Infectious Diseases 2009, 200, 390-398.

Duval X, Mentré F, Rey E, Auleley S, Peytavin G, Biour M, Métro A, Goujard C, Taburet AM, Lascoux C, Panhard X, Tréluyer JM, Salmon-Céron D, C2SG
Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen--ANRS 111 trial.
Fundamental & Clinical Pharmacology 2009, 23, 491-500.


Chenel M, Bouzom F, Cazade F, Ogungbenro K, Aarons L, Mentré F
Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 2: clinical trial results.
Journal of Pharmacokinetics and Pharmacodynamics 2008, 35, 661-681.

Comets E, Brendel K, Mentré F
Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R.
Computer Methods and Programs in Biomedicine 2008, 90, 154-166.

Guedeney A, Foucault C, Bougen E, Larroque B, Mentré F
Screening for risk factors of relational withdrawal behaviour in infants aged 14-18 months.
European Psychiatry: The Journal of the Association of European Psychiatrists 2008, 23, 150-155.

Bertrand J, Comets E, Mentre F
Comparison of model-based tests and selection strategies to detect genetic polymorphisms influencing pharmacokinetic parameters.
Journal of Biopharmaceutical Statistics 2008, 18, 1084-1102.

Essig M, Escoubet B, de Zuttere D, Blanchet F, Arnoult F, Dupuis E, Michel C, Mignon F, Mentre F, Clerici C, Vrtovsnik F
Cardiovascular remodelling and extracellular fluid excess in early stages of chronic kidney disease.
Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association 2008, 23, 239-248.

Hirt D, Mentré F, Tran A, Rey E, Auleley S, Salmon D, Duval X, Tréluyer JM, CASG
Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients.
British Journal of Clinical Pharmacology 2008, 65, 548-557.

Bellier C, Bert F, Durand F, Retout S, Belghiti J, Mentré F, Fantin B
Risk factors for Enterobacteriaceae bacteremia after liver transplantation.
Transplant International: Official Journal of the European Society for Organ Transplantation 2008, 21, 755-763.


Panhard X, Taburet AM, Piketti C, Mentré F
Impact of modelling intra-subject variability on tests based on non-linear mixed-effects models in cross-over pharmacokinetic trials with application to the interaction of tenofovir on atazanavir in HIV patients.
Statistics in Medicine 2007, 26, 1268-1284.

Retout S, Comets E, Samson A, Mentré F
Design in nonlinear mixed effects models: optimization using the Fedorov-Wynn algorithm and power of the Wald test for binary covariates.
Statistics in Medicine 2007, 26, 5162-5179.

Samson A, Lavielle M, Mentré F
The SAEM algorithm for group comparison tests in longitudinal data analysis based on non-linear mixed-effects model.
Statistics in Medicine 2007, 26, 4860-4875.

Comets E, Verstuyft C, Lavielle M, Jaillon P, Becquemont L, Mentré F
Modelling the influence of MDR1 polymorphism on digoxin pharmacokinetic parameters.
European Journal of Clinical Pharmacology 2007, 63, 437-449.

Panhard X, Legrand M, Taburet AM, Diquet B, Goujard C, Mentré F, C1A1SG
Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART.
European Journal of Clinical Pharmacology 2007, 63, 1019-1029.

Lavielle M, Mentré F
Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software.
Journal of Pharmacokinetics and Pharmacodynamics 2007, 34, 229-249.

Roussel R, Mentré F, Bouchemal N, Hadjadj S, Lièvre M, Chatellier G, Menard J, Panhard X, Le Hénanff A, Marre M, Le Moyec L, DSG
NMR-based prediction of cardiovascular risk in diabetes.
Nature Medicine 2007, 13, 399-400.

Collin F, Chêne G, Retout S, Peytavin G, Salmon D, Bouvet E, Raffi F, Garraffo R, Mentré F, Duval X, ACACSG
Indinavir trough concentration as a determinant of early nephrolithiasis in HIV-1-infected adults.
Therapeutic Drug Monitoring 2007, 29, 164-170.

Dartois C, Brendel K, Comets E, Laffont CM, Laveille C, Tranchand B, Mentre F, Lemenuel-Diot A, Girard P
Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey.
British Journal of Clinical Pharmacology 2007, 64, 603-612.

Karoubi Nordon E, Hayem G, Mentre F, Palazzo E, Legrain S, Meyer O, Raveau P
Late onset systemic lupus erythematosus: a new approach.
Lupus 2007, 16, 1011-1014.

Brendel K, Dartois C, Comets E, Lemenuel-Diot A, Laveille C, Tranchand B, Girard P, Laffont CM, Mentré F
Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004.
Clinical Pharmacokinetics 2007, 46, 221-234.

Bouaud J, Séroussi B, Brizon A, Culty T, Mentré F, Ravery V
How updating textual clinical practice guidelines impacts clinical decision support systems: a case study with bladder cancer management.
Studies in Health Technology and Informatics 2007, 129, 829-833.


Mentré F, Escolano S
Prediction discrepancies for the evaluation of nonlinear mixed-effects models.
Journal of Pharmacokinetics and Pharmacodynamics 2006, 33, 345-367.

Brendel K, Comets E, Laffont C, Laveille C, Mentré F
Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide.
Pharmaceutical Research 2006, 23, 2036-2049.

Samson A, Lavielle M, Mentre F
Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: Application to HIV dynamics model.
Computational Statistics & Data Analysis 2006, 51, 1562-1574.

Kaddouri H, Nakache S, Houzé S, Mentré F, Le Bras J
Assessment of the drug susceptibility of Plasmodium falciparum clinical isolates from africa by using a Plasmodium lactate dehydrogenase immunodetection assay and an inhibitory maximum effect model for precise measurement of the 50-percent inhibitory concentration.
Antimicrobial Agents and Chemotherapy 2006, 50, 3343-3349.

Berki-Benhaddad Z, Ecobichon JL, Mentré F, Capillon A, Certain A, Secondi C, Gervais A, Longuet P, Vildé JL, Leport C
[Adherence intervention for HIV-infected patients receiving antiretroviral treatment. Implementation and initial assessment].
Presse Médicale (Paris, France: 1983) 2006, 35, 1241-1248.


Bert F, Bellier C, Lassel L, Lefranc V, Durand F, Belghiti J, Mentré F, Fantin B
Risk factors for Staphylococcus aureus infection in liver transplant recipients.
Liver Transplantation: Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2005, 11, 1093-1099.

Panhard X, Mentré F
Evaluation by simulation of tests based on non-linear mixed-effects models in pharmacokinetic interaction and bioequivalence cross-over trials.
Statistics in Medicine 2005, 24, 1509-1524.

Jamois C, Comets E, Mentré F, Marion S, Farinotti R, Bonhomme-Faivre L
Pharmacokinetics and neutrophil toxicity of paclitaxel orally administered in mice with recombinant interleukin-2.
Cancer Chemotherapy and Pharmacology 2005, 55, 61-71.

Pillai GC, Mentré F, Steimer JL
Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science.
Journal of Pharmacokinetics and Pharmacodynamics 2005, 32, 161-183.

Guglielminotti J, Rackelboom T, Tesniere A, Panhard X, Mentre F, Bonay M, Mantz J, Desmonts JM
Assessment of the cough reflex after propofol anaesthesia for colonoscopy.
British Journal of Anaesthesia 2005, 95, 406-409.

Bourgoin H, Paintaud G, Büchler M, Lebranchu Y, Autret-Leca E, Mentré F, Le Guellec C
Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients.
British Journal of Clinical Pharmacology 2005, 59, 18-27.

Panhard X, Goujard C, Legrand M, Taburet AM, Diquet B, Mentre F
Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART.
British Journal of Clinical Pharmacology 2005, 60, 390-403.

Brendel K, Legrand M, Taburet AM, Baron G, Goujard C, Mentré F, C1A1TG
Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy.
Fundamental & Clinical Pharmacology 2005, 19, 373-383.

Driss F, Vrtovsnik F, Katsahian S, Michel C, Baron G, Kolta A, Sedrati N, Mentré F, Mignon F, Cabantchik I, Grandchamp B
Effects of intravenous polymaltose iron on oxidant stress and non-transferrin-bound iron in hemodialysis patients.
Nephron. Clinical Practice 2005, 99, c63-67.

Steg PG, Joubin L, McCord J, Abraham WT, Hollander JE, Omland T, Mentré F, McCullough PA, Maisel AS
B-type natriuretic peptide and echocardiographic determination of ejection fraction in the diagnosis of congestive heart failure in patients with acute dyspnea.
Chest 2005, 128, 21-29.

Duval X, Mentré F, Lamotte C, Chêne G, Spire B, Dellamonica P, Panhard X, Salmon D, Raffi F, Peytavin G, Leport C, ASG
Indinavir plasma concentration and adherence score are codeterminant of early virologic response in HIV-infected patients of the APROCO cohort.
Therapeutic Drug Monitoring 2005, 27, 63-70.

Verstuyft C, Marcellin F, Morand-Joubert L, Launay O, Brendel K, Mentré F, Peytavin G, Gérard L, Becquemont L, Aboulker JP, ASG
Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy.
AIDS (London, England) 2005, 19, 2127-2131.

Goujard C, Legrand M, Panhard X, Diquet B, Duval X, Peytavin G, Vincent I, Katlama C, Leport C, Bonnet B, Salmon-Céron D, Mentré F, Taburet AM, CA1SG
High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.
Clinical Pharmacokinetics 2005, 44, 1267-1278.


Barraud de Lagerie S, Comets E, Gautrand C, Fernandez C, Auchere D, Singlas E, Mentre F, Gimenez F
Cerebral uptake of mefloquine enantiomers with and without the P-gp inhibitor elacridar (GF1210918) in mice.
British Journal of Pharmacology 2004, 141, 1214-1222.

Duval X, Peytavin G, Albert I, Bénoliel S, Ecobichon JL, Brun-Vézinet F, Mentré F, Leport C, Vildé JL
Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients.
HIV medicine 2004, 5, 307-313.

Joly V, Descamps D, Peytavin G, Touati F, Mentre F, Duval X, Delarue S, Yeni P, Brun-Vezinet F
Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs.
Antimicrobial Agents and Chemotherapy 2004, 48, 172-175.

Trout H, Mentré F, Panhard X, Kodjo A, Escaut L, Pernet P, Gobert JG, Vittecoq D, Knellwolf AL, Caulin C, Bergmann JF
Enhanced saquinavir exposure in human immunodeficiency virus type 1-infected patients with diarrhea and/or wasting syndrome.
Antimicrobial Agents and Chemotherapy 2004, 48, 538-545.

Lamotte C, Landman R, Peytavin G, Mentre F, Gerbe J, Brun-Vezinet F, Boue F, Spiridon G, Valantin MA, Michelet C, Farinotti R, Yeni P
Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study).
Antiviral Therapy 2004, 9, 247-256.

Duval X, Pajot O, Le Moing V, Longuet P, Ecobichon JL, Mentre F, Leport C, Vilde JL
Maintenance therapy with cotrimoxazole for toxoplasmic encephalitis in the era of highly active antiretroviral therapy.
AIDS (London, England) 2004, 18, 1342-1344.

Rombout F, Aarons L, Karlsson M, Man A, Mentré F, Nygren P, Racine A, Schaefer H, Steimer JL, Troconiz I, van Peer A, CBE
Modelling and simulation in the development and use of anti-cancer agents: an underused tool?.
Journal of Pharmacokinetics and Pharmacodynamics 2004, 31, 419-440.


Panhard X, Dominique S, Gaub MP, Ravery V, Grandchamp B, Mentré F
Construction of a global score quantifying allelic imbalance among biallelic SIDP markers in bladder cancer.
Statistics in Medicine 2003, 22, 3771-3779.

Camus M, Hennere G, Baron G, Peytavin G, Massias L, Mentre F, Farinotti R
Comparison of lithium concentrations in red blood cells and plasma in samples collected for TDM, acute toxicity, or acute-on-chronic toxicity.
European Journal of Clinical Pharmacology 2003, 59, 583-587.

Comets E, Mentré F, Grass P, Kawai R, Marbach P, Vonderscher J
Population pharmacodynamic analysis of octreotide in acromegalic patients.
Clinical Pharmacology and Therapeutics 2003, 73, 95-106.

Retout S, Mentré F
Further developments of the Fisher information matrix in nonlinear mixed effects models with evaluation in population pharmacokinetics.
Journal of Biopharmaceutical Statistics 2003, 13, 209-227.

Imbert F, Jardin M, Fernandez C, Gantier JC, Dromer F, Baron G, Mentre F, Van Beijsterveldt L, Singlas E, Gimenez F
Effect of efflux inhibition on brain uptake of itraconazole in mice infected with Cryptococcus neoformans.
Drug Metabolism and Disposition: The Biological Fate of Chemicals 2003, 31, 319-325.

Crémieux AC, Muller-Serieys C, Panhard X, Delatour F, Tchimichkian M, Mentre F, Andremont A
Emergence of resistance in normal human aerobic commensal flora during telithromycin and amoxicillin-clavulanic acid treatments.
Antimicrobial Agents and Chemotherapy 2003, 47, 2030-2035.

Servin FS, Bougeois B, Gomeni R, Mentré F, Farinotti R, Desmonts JM
Pharmacokinetics of propofol administered by target-controlled infusion to alcoholic patients.
Anesthesiology 2003, 99, 576-585.

Retout S, Mentré F
Optimization of individual and population designs using Splus.
Journal of Pharmacokinetics and Pharmacodynamics 2003, 30, 417-443.


Retout S, Mentré F, Bruno R
Fisher information matrix for non-linear mixed-effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics.
Statistics in Medicine 2002, 21, 2623-2639.

Lucet JC, Rigaud MP, Mentre F, Kassis N, Deblangy C, Andremont A, Bouvet E
Hand contamination before and after different hand hygiene techniques: a randomized clinical trial.
Journal of Hospital Infection 2002, 50, 276-280.

Vrtovsnik F, Porcher R, Michel C, Hufnagel G, Queffeulou G, Mentré F, Mignon F
Survival of elderly patients on peritoneal dialysis: retrospective study of 292 patients, from 1982 to 1999.
Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis 2002, 22, 73-81.

Duffull SB, Retout S, Mentré F
The use of simulated annealing for finding optimal population designs.
Computer Methods and Programs in Biomedicine 2002, 69, 25-35.

Sasomsin P, Mentré F, Diquet B, Simon F, Brun-Vezinet F
Relationship between exposure to zidovudine and decrease of P24 antigenemia in HIV-infected patients in monotherapy.
Fundamental & Clinical Pharmacology 2002, 16, 347-352.


Retout S, Duffull S, Mentre F
Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs.
Computer Methods and Programs in Biomedicine 2001, 65, 141-151.

Aarons L, Karlsson MO, Mentre F, Rombout F, Steimer JL, van Peer A
Role of modelling and simulation in Phase I drug development.
European Journal of Pharmaceutical Sciences 2001, 13, 115-122.

Duffull SB, Mentre F, Aarons L
Optimal design of a population pharmacodynamic experiment for ivabradine.
Pharmaceutical Research 2001, 18, 83-89.

Mentre F, Dubruc C, Thenot JP
Population pharmacokinetic analysis and optimization of the experimental design for mizolastine solution in children.
Journal of Pharmacokinetics and Pharmacodynamics 2001, 28, 299-319.

Comets E, Mentre F
Evaluation of tests based on individual versus population modeling to compare dissolution curves..
Journal of biopharmaceutical statistics 2001, 11, 107-23.

Lechat P, Lardoux H, Mallet A, Sanchez P, Derumeaux G, Lecompte T, Maillard L, Mas JL, Mentre F, Pousset F, Lacomblez I, Pisica G, Solbes-Latourette S, Raynaud P, Chaumet-Riffaud P
Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation - A randomized trial (fluindione, fibrillation auriculaire, aspirin et contraste spontane; FFAACS).
Cerebrovascular Diseases 2001, 12, 245-252.


Comets E, Mentre F, Kawai R, Nimmerfall F, Marbach P, Vonderscher J
Modeling the kinetics of release of octreotide from long-acting formulations injected intramuscularly in rabbits.
Journal of Pharmaceutical Sciences 2000, 89, 1123-1133.

Deschamps C, Dubruc C, Mentre F, Rosenzweig P
Pharmacokinetic and pharmacodynamic modeling of mizolastine in healthy volunteers with an indirect response model.
Clinical Pharmacology & Therapeutics 2000, 68, 647-657.

Bert F, Galdbart JO, Zarrouk V, Le Mee J, Durand F, Mentre F, Belghiti J, Lambert-Zechovsky N, Fantin B
Association between nasal carriage of Staphylococcus aureus and infection in liver transplant recipients.
Clinical Infectious Diseases 2000, 31, 1295-1299.

Comets E, Pousset F, Mentre F, Diquet B, Ankri A, Mallet A, Lechat P
Prediction of fluindione maintenance dosage hampered by large intraindividual variability.
Therapeutic Drug Monitoring 2000, 22, 668-675.

Lechat P, Lardoux H, Mallet A, Sanchez P, Derumeaux G, Lecompte T, Maillard L, Mas JL, Mentre F, Pousset F, Lacomblez L, Pisica G, Solbes-Latourette S, Raynaud P, Chaumet-Riffaud P
Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation. A randomized trial (FFAACS).
Therapie 2000, 55, 681-689.


Comets E, Mentre F, Nimmerfall F, Kawai R, Mueller I, Marbach P, Vonderscher J
Nonparametric analysis of the absorption profile of octreotide in rabbits from long-acting release formulation OncoLAR.
Journal of Controlled Release 1999, 59, 197-205.

Merle Y, Mentre F
Optimal sampling times for Bayesian estimation of the pharmacokinetic parameters of nortriptyline during therapeutic drug monitoring.
Journal of Pharmacokinetics and Biopharmaceutics 1999, 27, 85-101.

Mentre F, Kovarik J, Gerbeau C
Constructing a prediction interval for time to reach a threshold concentration based on a population pharmacokinetic analysis: An application to basiliximab in renal transplantation.
Journal of Pharmacokinetics and Biopharmaceutics 1999, 27, 213-230.


Mentre F, Pousset F, Comets E, Plaud B, Diquet B, Montalescot G, Ankri A, Mallet A, Lechat P
Population pharmacokinetic-pharmacodynamic analysis of fluindione in patients.
Clinical Pharmacology & Therapeutics 1998, 63, 64-78.

Mentre F, Golmard JL, Launay JM, Aubin-Brunet V, Bouhassira M, Jouvent R
Relationships between low red blood cell count and clinical response to fluoxetine in depressed elderly patients.
Psychiatry Research 1998, 81, 403-405.

Aymard G, Legrand M, Comets E, Mentre F, Diquet B
Rapid and simple micromethod for the quantification of fluindione in human plasma using high-performance liquid chromatography.
Journal of Chromatography B 1998, 707, 169-173.

Patron-Bizet F, Mentre F, Genton M, Thomas-Haimez C, Maccario J
Assessment of the global two-stage method to EC50 determination.
Journal of Pharmacological and Toxicological Methods 1998, 39, 103-108.

Mesnil F, Mentre F, Dubruc C, Thenot JP, Mallet A
Population pharmacokinetic analysis of mizolastine and validation from sparse data on patients using the nonparametric maximum likelihood method.
Journal of Pharmacokinetics and Biopharmaceutics 1998, 26, 133-161.

Tod M, Mentre F, Merle Y, Mallet A
Robust optimal design for the estimation of hyperparameters in population pharmacokinetics.
Journal of Pharmacokinetics and Biopharmaceutics 1998, 26, 689-716.

Comets E, Mentre F, Pousset F, Diquet B, Montalescot G, Ankri A, Mallet A, Lechat P
Modeling INR data to predict maintenance fluindione dosage.
Therapeutic Drug Monitoring 1998, 20, 631-639.


Merle Y, Mentre F
Stochastic optimization algorithms of a Bayesian design criterion for Bayesian parameter estimation of nonlinear regression models: Application in pharmacokinetics.
Mathematical Biosciences 1997, 144, 45-70.

Mesnil F, Dubruc C, Mentre F, Huet S, Mallet A, Thenot JP
Pharmacokinetic analysis of mizolastine in healthy young volunteers after single oral and intravenous doses: Noncompartmental approach and compartmental modeling.
Journal of Pharmacokinetics and Biopharmaceutics 1997, 25, 125-147.

Jerling M, Merle Y, Mentre F, Mallet A
Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method.
British Journal of Clinical Pharmacology 1997, 44, 447-453.

Mentre F, Mallet A, Baccar D
Optimal design in random-effects regression models.
Biometrika 1997, 84, 429-442.

Lechat P, Canet E, Bellissant E, Billaud E, Brouard R, Bruguerolle B, Bruno R, Cudennec C, Degos L, Diquet B, Dubruc C, Garaffo R, Humbert H, Jochensen R, Laurent S, Laurin S, Laveille C, Mentre F, Paintaud G, Rosenzweig P, Simon P, Thibault N, Thuillez C, Warot D
Determination of time-dependent effect profile of drugs.
Therapie 1997, 52, 291-298.


Aarons L, Balant LP, Mentre F, Rowland M, Steimer JL, Vozeh S
Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies.
European Journal of Clinical Pharmacology 1996, 49, 251-254.

Vozeh S, Steimer JL, Rowland M, Morselli P, Mentre F, Balant LP, Aarons L
The use of population pharmacokinetics in drug development.
Clinical Pharmacokinetics 1996, 30, 81-93.

Burtin P, Mentre F, vanBree J, Steimer JL
Sparse sampling for assessment of drug exposure in toxicological studies.
European Journal of Drug Metabolism and Pharmacokinetics 1996, 21, 105-111.


Merle Y, Mentre F
Bayesian Design Criteria - Computation, Comparison, and Application to a Pharmacokinetic and a Pharmacodynamic Model.
Journal of Pharmacokinetics and Biopharmaceutics 1995, 23, 101-125.

Mentre F, Gomeni R
A two-step iterative algorithm for estimation in nonlinear mixed-effect models with an evaluation in population pharmacokinetics..
Journal of biopharmaceutical statistics 1995, 5, 141-58.

Mentré F, Burtin P, Merlé Y, Bree Jv, Mallet A, Steimer JL
Sparse-Sampling Optimal Designs in Pharmacokinetics and Toxicokinetics*.
Drug Information Journal 1995, 29, 997-1019.


Merle Y, Mentre F, Mallet A, Aurengo A
Designing an Optimal Experiment for Bayesian-Estimation - Application to the Kinetics of Iodine Thyroid Uptake.
Statistics in Medicine 1994, 13, 185-196.

Mentre F, Mallet A
Handling Covariates in Population Pharmacokinetics.
International Journal of Bio-Medical Computing 1994, 36, 25-33.

Taright N, Mentre F, Mallet A, Jouvent R
Nonparametric-Estimation of Population Characteristics of the Kinetics.
Therapeutic Drug Monitoring 1994, 16, 258-269.

Aarons L, Balant L, Mentre F, Morselli P, Rowland M, Steimer J, Vozeh S
Population Approaches in Drug Development - Report on an Expert Meeting.
European Journal of Clinical Pharmacology 1994, 46, 389-391.

Jerling M, Merle Y, Mentre F, Mallet A
Population Pharmacokinetics of Nortriptyline During Monotherapy and During Concomitant Treatment with Drugs That Inhibit Cyp2d6 - an Evaluation with the Nonparametric Maximum-Likelihood Method.
British Journal of Clinical Pharmacology 1994, 38, 453-462.

Gomeni R, Pineau G, Mentre F
Population-Kinetics and Conditional Assessment of the Optimal Dosage Regimen Using the P-Pharm Software Package.
Anticancer Research 1994, 14, 2321-2326.


Balant L, Rowland M, Aarons L, Mentre F, Morselli P, Steimer J, Vozeh S
New Strategies in Drug Development and Clinical-Evaluation - the Population Approach - Commentary on an Action for Cooperative Research.
European Journal of Clinical Pharmacology 1993, 45, 93-94.

Mentre F, Escolano S, Diquet B, Golmard J, Mallet A
Clinical Pharmacokinetics of Zidovudine - Inter and Intraindividual Variability and Relationship to Long-Term Efficacy and Toxicity.
European Journal of Clinical Pharmacology 1993, 45, 397-407.

Merle Y, Mentre F, Mallet A, Aurengo A
Computer-Assisted Individual Estimation of Radioiodine Thyroid Uptake in Graves-Disease.
Computer Methods and Programs in Biomedicine 1993, 40, 33-41.

Mignon F, Michel C, Mentre F, Viron B
Worldwide demographics and future trends of the management of renal failure in the elderly..
Kidney international. Supplement 1993, 41, S18-26.

Bindi P, Mougenot B, Mentre F, Noel L, Peraldi M, Vanhille P, Lesavre P, Mignon F, Ronco P
Necrotizing Crescentic Glomerulonephritis Without Significant Immune Deposits - a Clinical and Serological Study.
Quarterly Journal of Medicine 1993, 86, 55-68.


Mignon F, Michel C, Viron B, Mentre F, Jaar B
End-stage renal diseases in patients 75 and over: a new medical, socio-economical and ethical challenge..
The European journal of medicine 1992, 1, 302-7.

Escolano S, Mentre F, Golmard J, Diquet B, Mallet A
Plasma-Concentrations of Zidovudine.
New England Journal of Medicine 1992, 326, 1571-1571.


Coustere C, Mentre F, Sommadossi J, Diasio R, Steimer J
A Mathematical-Model of the Kinetics of 5-Fluorouracil and Its Metabolites in Cancer-Patients.
Cancer Chemotherapy and Pharmacology 1991, 28, 123-129.

Escolano S, Mentre F, Golmard J, Diquet B, Mallet A
A Reduced Dose of Zidovudine in Patients with Aids.
New England Journal of Medicine 1991, 324, 995-995.

Bindi P, Mougenot B, Mentre F, Noel L, Peraldi M, Vanhille P, Lesavre P, Mignon F, Ronco P
Necrotizing and Crescentic Glomerulonephritis Without Immunoglobulin Deposits - Renal Location of Systemic Vasculitis with Antineutrophil Cytoplasm Antibodies.
Presse Medicale 1991, 20, 1939-1943.


Leclercq J, Denjoy I, Mentre F, Coumel P
Flecainide Acetate Dose-Concentration Relationship in Cardiac-Arrhythmias - Influence of Heart-Failure and Amiodarone.
Cardiovascular Drugs and Therapy 1990, 4, 1161-1165.


Mallet A, Mentre F, Steimer J, Lokiec F
Nonparametric Maximum-Likelihood Estimation for Population Pharmacokinetics, with Application to Cyclosporine.
Journal of Pharmacokinetics and Biopharmaceutics 1988, 16, 311-327.

Mentre F, Mallet A, Steimer J
Hyperparameter Estimation Using Stochastic-Approximation with Application to Population Pharmacokinetics.
Biometrics 1988, 44, 673-683.

Mentre F, Mallet A, Steimer J, Lokiec F
An Application of Population Pharmacokinetics to the Clinical Use of Cyclosporine in Bone-Marrow Transplant Patients.
Transplantation Proceedings 1988, 20, 466-470.


Mentre F, Steimer J, Sommadossi J, Diasio R, Cano J
A Mathematical-Model of the Kinetics of 5-Fluorouracil and Its Catabolites in Freshly Isolated Rat Hepatocytes.
Biochemical Pharmacology 1984, 33, 2727-2732.